Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer

J Urol. 2013 Dec;190(6):2278-87. doi: 10.1016/j.juro.2013.07.001. Epub 2013 Jul 8.

Abstract

Purpose: To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo.

Materials and methods: Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo.

Results: MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice.

Conclusions: MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer.

Keywords: CCK-8; CRPC; Cell Counting Kit-8; LNCaP-AI; LNCaP-androgen independent subtype; M5; M9; MALAT-1; MALAT-1 siRNA-5; MALAT-1 siRNA-9; MALAT1 long non-coding RNA; PBS; PCR; PSA; RNA; RT-PCR; antiandrogens; castration resistant prostate cancer; human; lncRNA; long noncoding RNA; metastasis associated in lung adenocarcinoma transcript 1; phosphate buffered saline; polymerase chain reaction; prostate; prostate specific antigen; prostatic neoplasms; reverse transcriptase-PCR; small interfering.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Cycle / genetics
  • Humans
  • Male
  • Mice
  • Prostatic Neoplasms, Castration-Resistant / drug therapy
  • Prostatic Neoplasms, Castration-Resistant / genetics
  • Prostatic Neoplasms, Castration-Resistant / metabolism*
  • RNA, Long Noncoding / biosynthesis*
  • RNA, Long Noncoding / genetics
  • Tumor Cells, Cultured

Substances

  • MALAT1 long non-coding RNA, human
  • RNA, Long Noncoding